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Abstract
Background: Disruption of synaptic connectivity is a significant early event in many neurodegenerative conditions affecting
the aging CNS, including Alzheimer’s disease and Parkinson’s disease. Therapeutic approaches that protect synapses from
degeneration in the aging brain offer the potential to slow or halt the progression of such conditions. A range of animal
models expressing the slow Wallerian Degeneration (WldS) gene show robust neuroprotection of synapses and axons from a
wide variety of traumatic and genetic neurodegenerative stimuli in both the central and peripheral nervous systems, raising
that possibility that WldS may be useful as a neuroprotective agent in diseases with synaptic pathology. However, previous
studies of neuromuscular junctions revealed significant negative effects of increasing age and positive effects of gene-dose
on WldS-mediated synaptic protection in the peripheral nervous system, raising doubts as to whether WldS is capable of
directly conferring synapse protection in the aging brain.
Methodology/Principal Findings: We examined the influence of age and gene-dose on synaptic protection in the brain of
mice expressing the WldS gene using an established cortical lesion model to induce synaptic degeneration in the striatum.
Synaptic protection was found to be sensitive to WldS gene-dose, with heterozygous WldS mice showing approximately half
the level of protection observed in homozygousWldS mice. Increasing age had no influence on levels of synaptic protection.
In contrast to previous findings in the periphery, synapses in the brain of old WldS mice were just as strongly protected as
those in young mice.
Conclusions/Significance: Our study demonstrates that WldS-mediated synaptic protection in the CNS occurs
independently of age, but is sensitive to gene dose. This suggests that the WldS gene, and in particular its downstream
endogenous effector pathways, may be potentially useful therapeutic agents for conferring synaptic protection in the aging
brain.
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Introduction
Synaptic connections are an early pathological target in many
neurodegenerative conditions, ranging from Alzheimer’s disease,
prion diseases and Batten disease through to childhood and adult
forms of motor neuron disease [1–8]. Therapies directly
addressing synaptic degeneration are therefore actively being
sought for a wide range of neurological disorders. One promising
avenue of research in this area focuses on understanding the
neuroprotective properties of the slow Wallerian degeneration
(WldS) gene and its potential use as a novel synaptoprotective
agent.
The WldS gene confers strong neuroprotection upon synaptic
and axonal compartments of neurons following injury in both the
peripheral and central nervous systems [9,10], but has no direct
effect on neuronal soma [11]. These neuroprotective properties
significantly modify disease onset and/or progression in animal
models of chemically-induced Parkinson’s disease [12–13],
demyelinating neuropathies [14], some forms of motor neuron
disease [15] and global cerebral ischemia [16], highlighting the
potential use of WldS and/or its downstream mediators to generate
novel therapeutic approaches for the treatment of neurological
disorders. Importantly, it has also been demonstrated that the WldS
gene can be used to confer robust neuroprotection in vivo using
delivery methods including gene therapy [17,18], and that
systemic expression the WldS gene has no overt detrimental effects
on other non-neuronal systems, tissues or organs [19].
The chimeric WldS gene resulted from a spontaneous mutation
in the C57BL/6 line of mice, causing a tandem triplication in the
distal region of chromosome 4 [20]. Mice carrying the WldS gene
are otherwise indistinguishable from their C57BL/6J strain mates
in genotyping of more than 50 microsatellite markers and
restriction fragment length polymorphisms [21–23]. The triplicat-
ed region of chromosome 4 contains two copies of a fusion gene
comprising the N70 terminal amino acids of Ube4b and the
entire coding region of Nmnat1 (C Terminal 285 amino acids),
linked by 18 amino acids from the 59 untranslated region of Nmnat1
[20–21,24]. The chimeric portion of the triplication (i.e. the N-70
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Ube4b/Nmnat1 C-303 chimera) is sufficient to confer the full WldS
phenotype in mice, rats and drosophila [25–27], although its
mechanism of action remains controversial [18,28–32].
One potential caveat regarding the usefulness of the WldS
phenotype for protecting synapses in the brain concerns an age-
dependent aspect to WldS–mediated synaptic protection previously
revealed in the peripheral nervous system (PNS) [33]. This is of
particular importance as many neurodegenerative diseases affect-
ing the brain are associated with an aging population [34–35]. In
studies of axotomy-induced synaptic degeneration at the neuro-
muscular junction WldS mice older than 4 months began to lose
their synaptoprotective phenotype, with no synaptic protection
observed at all in mice older than 7 months [33]. By contrast,
axonal protection conferred by WldS in the PNS was shown to be
age-independent but highly sensitive to gene dose [25,33,36].
Similarly, synaptic protection in the PNS is known to be highly
sensitive to WldS gene dose [37]. Whether the synaptoprotective
phenotype observed in the CNS of young WldS mice [10,31] is also
sensitive to age and/or gene-dose has yet to be determined.
Here, we have undertaken a detailed study of the effects of gene-
dose and age on synaptic protection in the brain of WldS mice in vivo.
We show that synaptic protection medicated by WldS in the CNS
occurs independently of age, but is sensitive toWldS expression levels.
Results
Synaptic protection in the striatum of WldS mice is
sensitive to gene-dose
We have previously demonstrated robust protection of synapses
in the striatum following lesion to the cortico-striatal pathway in
young (,2 mth old) WldS mice [10]. We used the same model
system to assess the sensitivity of CNS synapses to WldS gene-dose
by quantifying synaptic pathology in the striatum of 2 mth old
wild-type (2/2), heterozygous WldS (+/2) and homozygous WldS
(+/+) mice following a cortical lesion. Experimental mice were
generated from heterozygous WldS (+/2) breeding pairs in order
to allow within litter comparisons.
Synaptic degeneration was induced in the striatum by
performing a lesion in the ipsilateral neocortex of wild-type,
heterozygous WldS and homozygous WldS mice using aspiration
under general anaesthesia (Figure 1A–B) [10]. Mice were allowed
to recover and were maintained for 3 days. A 3 day post-lesion
time-point was selected for examination as a result of previous
experimental data showing that the largest difference in synaptic
responses to injury between wild-type and homozygous WldS mice
occurred at 3 days post-lesion [10]. All mice recovered fully
following surgery with no discernable difference between the
Figure 1. Cortical lesion model for initiating synaptic degeneration in the striatum of wild-type, heterozygous WldS and
homozygousWldS mice. A/B – Schematic diagram of the mouse brain viewed from above (A), showing the extent of cortical lesion produced (grey
area). The dotted line in panel A represents the level of brain shown in coronal section in panel B (note the lesion to the left cortex). The box in panel
B shows the region of striatum selected for ultrastructural experiments. C – Quantitative fluorescent western blotting of protein extracted from tail
tips was used to confirm the genotype of experimental mice generated from heterozygous WldS (+/2) breeding colonies. Example blots show WldS
protein levels (red; labelled with the Wld-18 antibody specific for WldS protein) and levels of actin loading control (green) in tail tips from 18 mice. 2
membranes are shown side by side with randomly arranged samples from individual mice numbered 1–18. A molecular weight marker is also shown
(L). Lanes numbered 2,5,9,12 and 17 show wild-type mice (no WldS protein present), lanes 6,7,8,14,16 and 18 show heterozygous WldS mice
(intermediate levels of WldS protein present), and lanes 1,3,4,10,11,13 and 15 show homozygous WldS mice (high levels of WldS protein present). D/E
– Bar charts (mean6SEM) showing quantification of fluorescent western blots (see methods) shown in panel C (pooled to give a mean value for each
genotype), confirming that heterozygousWldS mice had approximately half the expression levels of WldS protein observed in homozygousWldS mice
(D), whilst levels of actin loading control remained constant (E) across mice of all genotypes. N= 5 wild-type mice, 6 heterozygous WldS mice & 7
homozygous WldS mice.
doi:10.1371/journal.pone.0015108.g001
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genotypes. Following sacrifice and perfusion fixation for electron
microscopy (see methods) the extent of the cortical lesion was
mapped in all mice to ensure comparability (Figure 1B). The
region of striatum selected for analyses of synaptic degeneration
was between 0.7 and 1.06 mm posterior to bregma, directly under
the corpus callosum at the level of the ventral border of the lateral
ventricle (Figure 1A–B) [38]. WldS protein levels in the brain were
determined using quantitative fluorescent western blotting. As
expected, wild-type mice showed no expression but heterozygous
mice had roughly half the levels of WldS protein observed in
homozygous mice (Figure 1C).
Qualitative ultrastructural analysis of synapses in the striatum of
wild-type mice 3 days after cortical lesion revealed a mixture of
normal synaptic profiles (identifiable as vesicle-laden boutons
separated by a synaptic cleft from a post-synaptic density; Figure 2)
as well as degenerating synapses, identified by their dark, electron-
dense cytoplasm and/or disrupted synaptic organelles (Figure 2)
[10,39–40]. These characteristics of degenerating synapses are
widely accepted to be the best early morphological indicators of
synaptic degeneration [10,39,40] and we did not identify any
obvious intermediate states preceding these morphological alter-
ations in our material. As in our previous study [10], virtually all
degenerating nerve terminals formed part of an asymmetrical
synapse, consistent with the glutamatergic nature of corticostriatal
projections (Figure 2). Qualitative assessment of heterozygous WldS
mice showed that degenerating synapses were present, but not in
the same numbers observed in wild-type animals. Degenerating
synapses were also present, but rare, in homozygous WldS mice.
Degeneration of post-synaptic striatal neurons was not observed in
any of the mice examined, in agreement with previous studies
suggesting that striatal neurons do not degenerate following
denervation [40–41].
Figure 2. Widespread synaptic degeneration in the striatum of young (2 month old) wild-type, but not heterozygous WldS or
homozygous WldS mice, 3 days after cortical lesion. Representative electron micrographs of striatal synapses at low power (A) and higher
power (B) from a young wild-type mouse (top panel), heterozygous WldS mouse (middle panel) and homozygous WldS mouse (bottom panel).
Asterisks indicate degenerating synaptic profiles (identified principally by their electron dense cytoplasm) and arrows indicate healthy (i.e. non-
degenerating) synaptic profiles. Degenerating synapses were readily identified in wild-type mice, occasionally observed in heterozygous WldS mice
and rarely observed in homozygous WldS mice. However, the morphological appearance of degenerating synapses was indistinguishable between
the different genotypes, suggesting that synapses in mice expressing the WldS gene ultimately degenerate by the same mechanism as in wild-type
mice, albeit after a delay. Scale bars; A = 1 mm, B= 0.5 mm.
doi:10.1371/journal.pone.0015108.g002
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Quantitative analyses of synaptic degeneration confirmed our
qualitative observations of dose-dependent CNS synaptic protec-
tion in WldS mice (Figure 3). Randomly-generated micrographs of
striatal tissue (see methods) were independently assessed by 3
experienced investigators. The results reported in Figure 3 are a
mean value from the 3 independent counts. All investigators were
blind to the genotype of the images being analysed. More than
23,000 individual synapses from 10 mice (4 wild-type, 3
heterozygous WldS and 3 homozygous WldS) were examined and
classified as either healthy or degenerating. At 3 days after cortical
lesion there were significantly more degenerating synaptic profiles
in the striatum of heterozygous WldS mice compared to
homozygous WldS mice (Figure 3A; P,0.05 ANOVA with
Tukey’s post-hoc test). There were also significantly more
degenerating synaptic profiles in the striatum of wild-type mice
compared to heterozygous WldS mice (Figure 3A; P,0.05).
Similarly, quantification of total (i.e. healthy and degenerating)
synaptic densities revealed a significant reduction in wild-type
mice compared to homozygous and heterozygous WldS mice
(Figure 3B). This demonstrated that the progression from
degeneration to complete loss of individual synapses had only
commenced in the wild-type mice, with the delay in degeneration
resulting in a retention of synapses in WldS-expressing mice.
To validate our ultrastructural findings and confirm the dose-
dependency of synaptic protection in the brains of WldS mice, we
examined synaptic degeneration in freshly prepared lesioned tissue
samples using quantitative fluorescent western blotting for synaptic
proteins (Figure 4). Expression levels of beta-SNAP were reduced
in the striatum of wild-type mice after cortical lesion compared to
homozygous WldS mice, with heterozygous WldS mice showing an
intermediate level of loss (Figure 4A,B). However, despite showing
similar trends to our ultrastructural data, the differences did not
reach statistical significance due to relatively large variability
between samples (Figure 4B). As beta-SNAP is a relatively soluble
protein and is not as enriched at synapses as other synaptic
markers, we repeated the experiment using antibodies against
synaptophysin and observed significant differences in levels
between homozygous WldS, heterozygous WldS, and wild-type
mice (Figure 4A,C). These results suggest that synaptophysin is a
more sensitive marker for synaptic pathology in the brain than
beta-SNAP.
Taken together, these data reveal that synaptic protection in the
CNS of WldS mice is sensitive to gene-dose. These findings also
confirm that the cortical lesion model is sensitive enough to detect
subtle changes in levels of synaptic degeneration and protection in
vivo using both ultrastructural and molecular approaches.
Synaptic protection in the striatum of WldS mice is not
diminished with increasing age
To test whether age influences the level of synaptic protection
conferred by WldS in the CNS, we performed cortical lesions in old
wild-type and WldS mice (aged ,12 months) and examined
synaptic pathology at 3 and 5 days post-surgery. Levels of WldS
protein in the brains of old WldS mice were at least as high as those
found in young (2 month old) WldS mice (data not shown) [33].
Qualitative ultrastructural analysis of synapses in the striatum of
old wild-type mice at both 3 and 5 days after cortical lesion
revealed a mixture of normal and degenerating synapses (Figure 5).
Degenerating synapses in old wild-type mice were morphologically
indistinguishable from those previously observed in young mice
(c.f. Figure 2 with Figure 5). In contrast, degenerating synapses
were rarely observed in old WldS mice at either 3 or 5 days post-
lesion (Figure 5).
Quantitative analyses, using the same methodology described
above for dose-dependency experiments, confirmed that increas-
ing age had no influence on synaptic protection in the CNS of
WldS mice (Figure 6). At both 3 and 5 days after cortical lesion
there were significantly more degenerating synaptic profiles in the
striatum of wild-type mice compared to homozygous WldS mice
(Figure 6A; P,0.01 ANOVA with Tukey’s post-hoc test).
Similarly, there were significantly fewer synapses remaining in
wild-type striatum compared to homozygous WldS tissue at both 3
and 5 days after cortical lesion (Figure 6; P,0.05 ANOVA with
Tukey’s post-hoc test). Thus, synaptic protection in the CNS of
WldS mice was not modified by age and was as robust in old CNS
synapses as in young CNS synapses.
Discussion
In this study we examined the influence of gene-dose and
increasing age on synaptic protection in the brain of mice
expressing the WldS gene. We demonstrate that synaptic
protection in the striatum was sensitive to WldS gene-dose
Figure 3. Quantitative analysis of synaptic degeneration
confirmed a dose-dependent protection of striatal synapses
inWldSmice 3 days after cortical lesion. A – Bar chart (mean6SEM)
showing the number of degenerating synapses in the striatum of wild-
type (WT), heterozygous WldS (Het) and homozygous WldS (Hom) mice
3 days after cortical lesion (***P,0.001, *P,0.05, ANOVA with Tukey’s
post-hoc test; N = 4 wild-type mice, 3 heterozygous WldS, 3 homozy-
gous WldS). B – Bar chart showing the total number of synapses
remaining in the striatum of wild-type (WT), heterozygous WldS (Het)
and homozygous WldS (Hom) mice 3 days after cortical lesion
(**P,0.01, *P,0.05, nsP.0.05, ANOVA with Tukey’s post-hoc test;
N = 4 wild-type mice, 3 heterozygous WldS, 3 homozygous WldS).
doi:10.1371/journal.pone.0015108.g003
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following cortical lesion, with heterozygous WldS mice showing
approximately half the level of protection observed in homozygous
WldS mice. In contrast, we show that increasing age had no
influence on levels of synaptic protection in the brain, revealing
different synaptoprotective phenotypes in the CNS and PNS of old
(.7 mth) WldS mice. Taken together, these findings suggest that
WldS-mediated neuroprotection is likely to be of potential
therapeutic benefit for conferring synaptic protection in the aging
brain. Importantly, our finding that synaptic protection in the
brain is sensitive to WldS gene-dose suggests that delivery of higher
levels of WldS to neurons could provide robust long-lasting synaptic
protection, even in the aging nervous system.
Our finding that synaptic protection in the brain of old WldS
mice occurred just as robustly as in young (,2 mth) WldS mice is
in stark contrast to events occurring at synapses in the mouse PNS.
It is well established that full WldS-mediated protection of
neuromuscular synapses is only present in mice up to 4 months
of age, with mice of 7 months or older reverting to wild-type
synaptic degeneration characteristics [33]. The reasons for this
difference remain unclear. One possibility is that synaptic
degeneration occurs via subtly distinct mechanisms in the CNS
and PNS. This hypothesis is supported by data from current and
previous experiments [10] which demonstrated that brain synapses
degenerate by the same cellular pathways in wild-type and WldS
mice (albeit delayed in the latter), whereas neuromuscular synapses
in WldS mice degenerate via a withdrawal-like mechanism
morphologically and mechanistically distinct from the classical
Wallerian degeneration process that occurs in wild-type mice
[33;42–43]. It is possible, therefore, that the pathways regulating
synaptic degeneration in the PNS have age-dependent character-
istics that do not impact on pathways regulating synaptic
degeneration in the brain.
A recent study from Beirowski and colleagues demonstrated that
the efficacy of WldS–mediated protection is regulated by protein
levels in the cytoplasm and/or non-nuclear organelles, rather than
protein levels in the nucleus [44]. This raises the possibility that the
strong, age-independent synaptic protection we observed in the
brain was occurring due to neurons in the brain having
consistently higher non-nuclear levels of WldS protein expression
than motor neurons in the periphery. Alternatively, data from
transgenic rats expressing the WldS gene suggest that the age-
dependent characteristics of neuroprotection at peripheral synap-
ses are dependent on the presence of long distal nerve stumps,
particularly in older animals [26]. This dependency on nerve
stump length might not be an important factor for CNS neurons.
Future experiments addressing issues of non-nuclear WldS protein
expression and nerve stump length for synaptic protection in the
brain are therefore warranted.
Regardless of the differences observed between the CNS and
PNS, the current study raises the exciting possibility that the WldS
gene, and in particular its downstream endogenous effector
pathways, could potentially be useful therapeutic agents for
conferring synaptic protection in the aging brain and central
nervous system. Systemic delivery of the WldS gene targeting
neurones in the brain is possible using gene therapy approaches
[17,18], and WldS gene expression is safe and well-tolerated by
other body systems and organs [19]. However, a more interesting
and realistic therapeutic approach would be to target endogenous
cellular pathways that are themselves targeted by WldS in
neurones. Recent breakthroughs in our understanding of the
mechanism of action of WldS have highlighted several potential
effector pathways and sub-cellular targets that may be suitable as
therapeutic targets [28], including; Nmnat-dependent pathways
[18,45–46], mitochondria [31,47–48], VCP-dependent pathways
[49,50], and cell cycle/cell stress pathways [32,51]. The current
study suggests that manipulating one or several of these pathways
or targets, in a similar manner and extent to that generated by the
WldS gene in vivo, should confer synaptic protection in the aging
brain. Downstream endogenous mediators of synaptic protection
conferred by the WldS gene are therefore attractive targets for
Figure 4. Quantitative western blotting for synaptic proteins
confirmed dose-dependent protection of striatal synapses in
WldS mice 3 days after cortical lesion. A – Representative bands
from western blots showing expression levels of two major synaptic
proteins (SNAP and synaptophysin) as well as two loading controls
(actin and tubulin) in the striatum of wild-type, heterozygous WldS and
homozygous WldS mice 3 days after cortical lesion. Note lower levels of
synaptic markers in heterozygous WldS mice compared to homozygous
WldS mice and lower still levels in wild-type mice, indicative of a loss of
synapses. B/C – Bar charts (mean6SEM) showing relative expression
levels of SNAP (B) and synaptophysin (C) in the striatum of wild-type,
heterozygous WldS and homozygous WldS mice 3 days after cortical
lesion (ns = not significant, *P,0.05, ***P,0.001; ANOVA with Tukey’s
post-hoc test; N = 3 mice per genotype). Levels of actin and tubulin
remained constant between samples (data not shown but see Panel A).
doi:10.1371/journal.pone.0015108.g004
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designing synaptoprotective therapeutic strategies for age-related
neurodegenerative diseases affecting the brain, including Alzhei-
mer’s disease and Parkinson’s disease.
Materials and Methods
Ethics statement
All animal experiments were approved by a University of
Edinburgh internal ethics committee and were performed under
license by the UK Home Office (project license number 60/3891).
Mice
Natural mutant homozygous C57Bl6/WldS (WldS) mice and
C57Bl6 (wild-type) mice aged 2 months were obtained from
Harlan Olac Laboratories (Bicester, UK) and housed within the
animal care facilities in Edinburgh. A breeding program was
undertaken to obtain mice heterozygous for the WldS gene. These
heterozygous mice were then cross-bred to obtain litters
containing mice homozygous and heterozygous for the WldS gene
as well as wild-type littermates, facilitating within litter compar-
isons. Young mice were used for experiments at 6-10 weeks of age.
A cohort of mice were also maintained in animal care facilities in
Edinburgh for the aging experiments. Mice were genotyped using
either qRT-PCR [52] or quantitative fluorescent western blotting
(see below) [19].
Surgery
All operations were performed under licence from the UK
Home Office. General anaesthesia was induced using a mixture of
isopentane and oxygen, before securing the head in a Kopf
stereotaxic frame. Fur overlying the cranial vault was shaved with
scissors before making an incision through the skin at the midline.
Four holes were drilled on the left side of skull; 1) in the midline at
bregma, 2) in line with the first but at the level of lambda, 3)
further caudal on the lateral side just above the temporalis muscle,
4) anterolateral in line with the first and third holes. The skull was
cut in lines connecting all holes except the most caudal border, and
then reflected. A suction pipette was used to remove all visible
cortex under a dissecting microscope, down to the level of the
corpus callosum, before replacing the skull-flap. The lesion site was
filled with gel foam (Ethicon) before replacing the skull-flap.
Overlying skin was then sutured and the mouse placed on a heated
blanket until recovered fully from the anaesthetic. Mice were
maintained in standard animal house conditions and were checked
daily for any signs of distress or discomfort.
Electron microscopy
Three days after surgery, anaesthetised mice were killed by
perfusion fixation with 0.1 M phosphate buffer containing 4%
paraformaldehyde and 2.5% glutaraldehyde, before removing the
brain and immersing in fixative for a further 12–24 hrs. Brains
were washed in 0.1 M phosphate buffer before cutting free-
floating 70 mm thick coronal sections on a vibratome. The region
of striatum used for analysis of synaptic pathology was located
between 0.70 and 1.06 mm posterior to Bregma, directly under
the corpus callosum at the level of the ventral border of the lateral
ventricle. Vibratome sections containing this region were post-
fixed in 1% osmium tetroxide for 45 minutes and dehydrated
through an ascending series of ethanol solutions (including
dehydration for 40 mins in 70% alcohol containing 1% uranyl
acetate) and propylene oxide. Sections were embedded on glass
slides in Durcupan resin. Regions of striatum (,1 mm61 mm) to
Figure 5. Synaptic protection in the striatum remains robust in old (,12 month old) homozygous WldS mice after cortical lesion.
Representative electron micrographs of striatal synapses at low power (A) and higher power (B) from an old wild-type mouse (top panel) and old
homozygous WldS mouse (bottom panel) 3 days after cortical lesion. Asterisks indicate degenerating synaptic profiles (identified principally by their
electron dense cytoplasm) and arrows indicate healthy (i.e. non-degenerating) synaptic profiles. Degenerating synapses were readily identified in
wild-type mice but rarely observed in homozygous WldS mice. As in young mice (see Figure 2), the morphological appearance of degenerating
synapses was indistinguishable between the different genotypes. Scale bars; A = 1 mm, B = 0.5 mm.
doi:10.1371/journal.pone.0015108.g005
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be used for quantitative assessment were cut out from a randomly
selected section using a scalpel and glued onto a resin block for
ultrathin sectioning. Ultrathin sections (,50–70 nm) were cut and
collected on formvar-coated grids (Agar Scientific, UK), stained
for 10 mins with lead citrate, and then viewed using a Philips
CM12 transmission electron microscope. Images were captured
directly using a Gatan digital camera and were quantified using
Image J software (version 1.35c).
Images were taken at random locations within each grid (e.g.
starting at the top corner of the section before progressing across
the section in a direction dictated by the loading position of the
grid in the microscope) and quantified independently by 3
investigators, with each of the investigators blind to the genotype
of the images being assessed. Average data from the three
individual assessments were used for comparison between
genotypes. Standard ultrastructural characteristics were used to
define healthy and degenerating synapses. Normal synaptic
terminals were located by the presence of vesicle-filled pre-
synaptic boutons, separated from their post-synaptic target by a
clear synaptic cleft. Degenerating synapses were identified by their
dark, electron dense cytoplasm, often containing disrupted
synaptic vesicles and mitochondria, consistent with previous
ultrastructural studies of degenerating synapses [10,39–40].
Numbers of degenerating and healthy synapses were counted in
each electron micrograph. Of those synaptic profiles that crossed a
border of the micrograph, only those that crossed the top and left
hand borders of the image were included, with those crossing the
bottom and lower borders being excluded.
Western blotting
For genotyping mice, tail tips were removed from freshly
sacrificed mice and assayed for the level of WldS protein
expression. This was possible as WldS protein has previously been
shown to be expressed in a wide range of tissues and organs,
including muscle and skin of the tail [19]. Brains for quantification
of synaptic proteins were rapidly removed and briefly chilled in ice
cold ACSF (125 mM NaCl, 26 mM NaHCO3, 25 mM glucose,
2.5 mM KCl, 1.25 mM NaH2PO4, 1 mM CaCl2, 4 mMMgCl2)
before striata were microdissected out.
Quantitative fluorescent western blotting was performed as
previously described [53–55]. Briefly, membranes were incubated
with primary antibodies as per manufacturers instructions
(synaptophysin – Dako; b actin, b SNAP & bIII tubulin –
Abcam). Wld-18 antibodies, selective only for the chimeric WldS
protein [16,19,25], were a kind gift from Dr Michael Coleman
(Babraham Institute, Cambridge). Odyssey secondary antibodies
were added according to manufacturers instructions (Goat anti
rabbit IRDye 680 or 800 and Goat anti mouse IRDye 680 or 800
Figure 6. Quantitative analysis of synaptic degeneration confirmed robust protection of striatal synapses in old (,12 mth) WldS
mice 3 and 5 days after cortical lesion. A – Bar chart (mean6SEM) showing the number of degenerating synapses in the striatum of wild-type
(WT) and homozygous WldS (Wlds) mice at 3 and 5 days after cortical lesion (**P,0.01, ANOVA with Tukey’s post-hoc test; N = 4 wild-type mice per
time-point, 3 homozygousWldS mice per time-point). B – Bar chart showing the total number of synapses remaining in the striatum of wild-type and
homozygous WldS mice at 3 and 5 days after cortical lesion (*P,0.05, nsP.0.05, ANOVA with Tukey’s post-hoc test; N = 4 wild-type mice per time-
point, 3 homozygous WldS mice per time-point).
doi:10.1371/journal.pone.0015108.g006
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– dependant on required comparisons). Blots were imaged using
an Odyssey Infrared Imaging System (Li-COR Biosciences) at
either 84 mm or 169 mm resolution.
Statistical analysis
All data were collected into Microsoft Excel spreadsheets and
analysed using GraphPad Prism software. All bar charts shown are
mean 6 SEM. Statistical significance was considered to be
p,0.05 for all analyses. Individual statistical tests used are detailed
in figure legends.
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